EMERYVILLE, Calif., May 2, 2023 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today reported financial results and provided a business update for the quarter ended March 31, 2023.
Read more at prnewswire.comProvided Content: Content provided by PR Newswire. The Globe and Mail was not involved, and material was not reviewed prior to publication.